EUVIMEDEUVIMED entdecken
Crossref

Dual-energy computed tomography for predicting histological grading and survival in patients with pancreatic ductal adenocarcinoma

Weiyue Chen, Guihan Lin, Xia Li, Ye Feng, Weibo Mao, Chunli Kong, Yumin Hu, Yang Gao, Weibin Yang, Minjiang Chen, Zhihan Yan, Shuiwei Xia und 3 weitere

European Radiology · 16.10.2024 · 35 (5) · 2818-2832

DOI: 10.1007/s00330-024-11109-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Radiology, online erschienen am 16.10.2024. Verfasst von Weiyue Chen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biote…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Tomography, X-Ray Computed, Radiography, Dual-Energy Scanned Projection. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Medical and Health General Project of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: We evaluated the value of dual-energy computed tomography (DECT) parameters derived from pancreatic ductal adenocarcinoma (PDAC) to discriminate between high- and low-grade tumors and predict overall survival (OS) in patients. METHODS: Data were retrospectively collected from 169 consecutive patients with pathologically confirmed PDAC who underwent third-generation dual-source DECT enhanced dual-phase scanning before surgery between January 2017 and March 2023. Patients with prior treatments, other malignancies, small tumors, or poor-quality scans were excluded. Two radiologists evaluated three clinical and seven radiological features and measured sixteen DECT-derived parameters. Univariate and multivariate analyses were applied to select independent predictors. A prediction model and a corresponding nomogram were developed, and the area under the curve (AUC), calibration, and clinical applicability were assessed. The correlations between factors and OS were evaluated using Kaplan-Meier survival and Cox regression analyses. RESULTS: One hundred sixty-nine patients were randomly divided into training (n = 118) and validation (n = 51) cohorts, among which 43 (36.4%) and 19 (37.3%) had high-grade PDAC confirmed by pathology, respectively. The vascular invasion, normalized iodine concentration in the venous phase, and effective atomic number in the venous phase were independent predictors for histological grading. A nomogram was constructed to predict the risk of high-grade tumors in PDAC, with AUCs of 0.887 and 0.844 in the training and validation cohorts, respectively. The nomogram exhibited good calibration and was more beneficial than a single parameter in both cohorts. Pathological- and nomoscore-predicted high-grade PDACs were associated with poor OS (all p < 0.05). CONCLUSIONS: The nomogram, which combines DECT parameters and radiological features, can predict the histological grade and OS in patients with PDAC before surgery. KEY POINTS: Question Preoperative determination of histological grade in PDAC is crucial for guiding treatment, yet current methods are invasive and limited. Findings A DECT-based nomogram combining vascular invasion, normalized iodine concentration, and effective atomic number accurately predicts histological grade and OS in PDAC patients. Clinical relevance The DECT-based nomogram is a reliable, non-invasive tool for predicting histological grade and OS in PDAC. It provides essential information to guide personalized treatment strategies, potentially improving patient management and outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsTomography, X-Ray ComputedRadiography, Dual-Energy Scanned ProjectionHumansFemaleMaleMiddle AgedAgedRetrospective StudiesNeoplasm GradingNomogramsAged, 80 and overAdult

Stichwörter der Autor:innen

Dual-energy computed tomographyHistological gradeOverall survivalPancreatic ductal adenocarcinomaPrediction model

Autor:innen und Institutionen

  • Zhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Engineering Research Center of Interventional Medicine Engineering and Biotechnology, Key Laboratory of Precision Medicine of Lishui City, The Fif…
  • Clinical College of The Affiliated Central Hospital, School of Medicine, Lishui University, Lishui, China.
  • Department of Pathology, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, China.
  • Wenzhou Key Laboratory of Structural and Functional Imaging, Wenzhou, China.
  • Clinical College of The Affiliated Central Hospital, School of Medicine, Lishui University, Lishui, China. jjstcty@wmu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Medical and Health General Project of Zhejiang Province

Zitieren

APA

Chen, W., Lin, G., Li, X., Feng, Y., Mao, W., Kong, C., Hu, Y., Gao, Y., Yang, W., Chen, M., Yan, Z., Xia, S., Lu, C., Xu, M., & Ji, J. (2024). Dual-energy computed tomography for predicting histological grading and survival in patients with pancreatic ductal adenocarcinoma. European Radiology, 35(5), 2818-2832. https://doi.org/10.1007/s00330-024-11109-4

Vancouver

Chen W, Lin G, Li X, Feng Y, Mao W, Kong C, et al. Dual-energy computed tomography for predicting histological grading and survival in patients with pancreatic ductal adenocarcinoma. European Radiology. 2024;35(5):2818-2832. doi:10.1007/s00330-024-11109-4

BibTeX
@article{Chen2024,
  author = {Chen, Weiyue and Lin, Guihan and Li, Xia and Feng, Ye and Mao, Weibo and Kong, Chunli and Hu, Yumin and Gao, Yang and Yang, Weibin and Chen, Minjiang and Yan, Zhihan and Xia, Shuiwei and Lu, Chenying and Xu, Min and Ji, Jiansong},
  title = {Dual-energy computed tomography for predicting histological grading and survival in patients with pancreatic ductal adenocarcinoma},
  journal = {European Radiology},
  year = {2024},
  volume = {35},
  number = {5},
  pages = {2818--2832},
  doi = {10.1007/s00330-024-11109-4}
}
Kostenlos starten →